United Therapeutics Q3 2026 slides: record revenue, robust pipeline
United Therapeutics (UTHR) reported Q3 2026 revenue of $833M, up 4% YoY, but missed EPS estimates, causing a 2.75% stock decline. Tyvaso franchise revenue grew 5% YoY to $504M. The company advanced its pipeline, with FDA accepting applications for Tyvaso in IPF and ralinepag in PAH, both with 2027 PDUFA dates. Operating cash flow was $1.4B, and a $2B share repurchase program was authorized.
How this was made
The 30-second read
Why it matters
The most tradable elements are the FDA’s acceptance of supplemental NDAs with specific 2027 PDUFA dates and the quantified franchise performance, partially offset by an EPS miss versus consensus and stated cost pressures.
Market read
Traders can update 2027 catalyst calendars (PDUFA dates) and reassess near-term fundamentals using the reported Q3 revenue mix and EPS miss.
What to watch
Tyvaso growth is attributed to execution and dosing options, so traders may want to monitor sustainability of referral and adoption trends, and the competitive impact of the Liquidia settlement on label dynamics.
Background
United Therapeutics’ Q3 2026 update emphasizes a transition from PAH roots toward broader respiratory indications and regenerative medicine, anchored by Tyvaso and ralinepag progress.
Ticker impact
United Therapeutics reports Q3 2026 record revenue and details FDA-accepted supplemental NDAs for nebulized Tyvaso in IPF and ralinepag in PAH.
Likely mixed-to-positive repricing as traders weigh FDA filing acceptance and pipeline momentum against the reported EPS shortfall and cost pressure narrative.
The article provides specific FDA acceptance events with PDUFA dates and quantifies revenue by franchise, while also stating EPS missed consensus and the stock fell on the day.
Market effects
Reinforces competitive intensity in prostacyclin-based respiratory therapies and highlights FDA review timelines as a key catalyst for PAH and pulmonary fibrosis names.
Limited direct regional spillover beyond US-listed biotech/respiratory peers.
Primarily US regulatory-driven; global investors may adjust expectations for respiratory drug review cadence and trial-to-filing translation.
Counterpoint
The FDA acceptance is not the same as approval, and the article’s EPS miss plus cost-pressure language could dominate near-term valuation until clearer regulatory outcomes arrive.
Key entities
- companyUnited Therapeutics Corporation
Reports Q3 2026 record revenue, EPS shortfall, a new $2B repurchase authorization, and FDA-accepted supplemental NDAs for Tyvaso (IPF) and ralinepag (PAH).
- regulatorFDA
Accepted supplemental NDA for nebulized Tyvaso in IPF (PDUFA April 26, 2027) and NDA for ralinepag in PAH (PDUFA June 24, 2027).
- productTyvaso (nebulized and DPI)
Flagship franchise with record Q3 revenue and pivotal TETON program data supporting IPF filing acceptance.
- productralinepag
Once-daily oral prostacyclin with ADVANCE OUTCOMES efficacy supporting PAH NDA acceptance.
